At Week 52 of Treatment (SINUS-52), DUPIXENT Demonstrated1:

-1.34
IMPROVEMENT
IN NC SCORE

LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -1.13 (95% CI: -1.49, -0.77) (-1.34 from a baseline score of 2.38 vs -0.21 from a baseline score of 2.49, respectively).1

-2.54
IMPROVEMENT
IN NPS

LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -2.57 (95% CI: -3.27, -1.87) (-2.54 from a baseline score of 5.87 vs 0.03 from a baseline score of 6.06, respectively).1

-7.27
IMPROVEMENT
IN LMK-CT SCORE

LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -6.86 (95% CI: -8.62, -5.10) (-7.27 from a baseline score of 19.71 vs -0.41 from a baseline score of 19.07, respectively).1

Analysis was not multiplicity controlled; results are descriptive; definitive conclusions cannot be made.1


27% of patients enrolled in SINUS-52 presented with NSAID‑ERD2

Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.2

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal
endoscopy: reduced score indicates improvement.2

Lund-Mackay computed tomography (LMK-CT) score (range 0-24): reduced score indicates improvement.2

INCS, intranasal corticosteroid; LSM, least squares mean; NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory
disease; Q2W, once every 2 weeks.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.2

SEE SAFETY DATA
BACK TO LMK-CT RESULTS

Explore the Safety Data
and Study Designs

View Safety Data See the full study designs

Dosage and
Administration

See the recommended dosing and
administration options for patients
on DUPIXENT.

Explore ADMINISTRATION Options